Phase II randomized, placebo-controlled trial of phytotherapeutic product Catuama for breast cancer women undergoing adjuvant radiation therapy.

医学 安慰剂 乳腺癌 医院焦虑抑郁量表 内科学 随机对照试验 生活质量(医疗保健) 癌症 不利影响 萧条(经济学) 外科 焦虑 精神科 病理 护理部 经济 替代医学 宏观经济学
作者
Felipe Melo Cruz,Daniel de Iracema Gomes Cubero,Patrícia Xavier Santi,Luciana Garcia Landeiro,Andressa Sayuri Tamashiro,Larisse Soares Ribeiro,Auro del Giglio
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:31 (15_suppl): e20524-e20524
标识
DOI:10.1200/jco.2013.31.15_suppl.e20524
摘要

e20524 Background: Fatigue and Depression are common in patients undergoing Breast Cancer (BC) treatment. Catuama is a registered phytotherapic that contains 4 brazilian herbs per capsule: Trichilia catigua (87.5mg), Ptychopetalum olacoides (87.5mg), Paullinia cupana (125 mg) and Zingiber officinale (10mg). Objectives: Since one of its constituents is Guarana (Paulinia cupana) which we already reported to have anti-fatigue effects, we decided to test Catuama potential anti-fatigue effects in BC women undergoing adjuvant 4 weeks of Radiation Therapy (RxT). Methods: This is a double blinded, randomized, placebo-controlled, Phase II cross-over trial. Patients with histologically proven BC with the indication of adjuvant RxT, non-pregnant nor breastfeeding, older than 18 years of age, with ECOG PS 0 or 1, without a history of cardiac, renal, hepatic or psychiatric decompensation, received Catuama 1 capsule twice daily versus a matching placebo for the first 2 weeks of RxT treatment, followed by a week of wash out, followed by an additional two weeks of treatment with crossover of experimental arms. Patients were evaluated on days 1, 15 and 36 with the Brief Fatigue Inventory (BFI), Hospital Anxiety and Depression Scale (HADS), Quality of Life FACIT-F, FACIT-ES questionnaires, and Chalder Fatigue scale. Results: We enrolled 90 patients with a median age of 53 years (26 – 80). We saw no statistically significant differences of FACIT ES, FACIT F, HADS, Chalder or BFI scores treated with Catuama or Placebo when we considered all included patients. When we selected only patients with a BFI score above 30, Catuama significantly decreased BFI scores as compared to baseline (p<0.0001). We observed one instance of grade 3 hypermagnesemia in the Catuama arm and one patient had hyperglicemia grade 3 both in the Catuama and in the placebo arm. No grade 4 toxicities were seen. Conclusions: Catuama may help selected patients who already start RxT with evidence of fatigue.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
Aries完成签到,获得积分10
1秒前
lt发布了新的文献求助10
1秒前
文人青完成签到 ,获得积分10
2秒前
哈哈哈完成签到 ,获得积分10
2秒前
动听千秋完成签到 ,获得积分10
3秒前
科研通AI2S应助背后半烟采纳,获得10
4秒前
杳鸢应助谷安采纳,获得20
4秒前
Rutin发布了新的文献求助10
7秒前
lt完成签到,获得积分10
11秒前
12秒前
14秒前
Crystal发布了新的文献求助10
14秒前
14秒前
阳光的紫丝完成签到 ,获得积分10
16秒前
zhc发布了新的文献求助10
16秒前
FashionBoy应助火星上冬莲采纳,获得10
16秒前
大黄应助曾经问雁采纳,获得10
16秒前
zszzzsss发布了新的文献求助30
20秒前
21秒前
答案。完成签到 ,获得积分10
22秒前
Rutin完成签到,获得积分10
24秒前
科研通AI2S应助背后半烟采纳,获得10
25秒前
siriuslee99发布了新的文献求助10
27秒前
拼搏凝蕊发布了新的文献求助10
28秒前
29秒前
粗暴的无色完成签到 ,获得积分10
29秒前
白华苍松发布了新的文献求助10
29秒前
晏晏完成签到 ,获得积分10
30秒前
pophoo发布了新的文献求助10
31秒前
深情安青应助林lin采纳,获得10
31秒前
lilyyun1990发布了新的文献求助10
32秒前
加油鸭鸭鸭完成签到,获得积分10
32秒前
yoonkk完成签到,获得积分10
33秒前
Sean完成签到 ,获得积分10
38秒前
NexusExplorer应助36456657采纳,获得10
40秒前
科研通AI2S应助背后半烟采纳,获得10
41秒前
42秒前
科研通AI2S应助负责之卉采纳,获得10
43秒前
高分求助中
Evolution 3rd edition 1500
Lire en communiste 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 700
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
2-Acetyl-1-pyrroline: an important aroma component of cooked rice 500
Ribozymes and aptamers in the RNA world, and in synthetic biology 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3180905
求助须知:如何正确求助?哪些是违规求助? 2831086
关于积分的说明 7983117
捐赠科研通 2493070
什么是DOI,文献DOI怎么找? 1329957
科研通“疑难数据库(出版商)”最低求助积分说明 635872
版权声明 602954